$54.89
0.81% day before yesterday
Nasdaq, Oct 24, 10:00 pm CET
ISIN
GB00BYMT0J19
Symbol
LIVN

Livanova PLC Stock price

$54.89
+1.66 3.12% 1M
+17.63 47.32% 6M
+8.58 18.53% YTD
+1.97 3.72% 1Y
+9.90 22.00% 3Y
+2.35 4.47% 5Y
-10.35 15.86% 10Y
+23.35 74.03% 20Y
Nasdaq, Closing price Fri, Oct 24 2025
+0.44 0.81%

Key metrics

Basic
Market capitalization
$3.0b
Enterprise Value
$2.8b
Net debt
positive
Cash
$593.6m
Shares outstanding
54.6m
Valuation (TTM | estimate)
P/E
negative | 14.4
P/S
2.3 | 2.2
EV/Sales
2.2 | 2.1
EV/FCF
17.5
P/B
2.7
Financial Health
Equity Ratio
52.7%
Return on Equity
4.8%
ROCE
11.2%
ROIC
16.6%
Debt/Equity
0.4
Financials (TTM | estimate)
Revenue
$1.3b | $1.4b
EBITDA
$231.9m | $326.2m
EBIT
$188.7m | $280.6m
Net Income
$-211.3m | $208.8m
Free Cash Flow
$162.1m
Growth (TTM | estimate)
Revenue
8.2% | 10.1%
EBITDA
51.5% | 59.6%
EBIT
77.0% | 73.1%
Net Income
-1,173.8% | 230.1%
Free Cash Flow
90.2%
Margin (TTM | estimate)
Gross
69.1%
EBITDA
17.7% | 23.6%
EBIT
14.4%
Net
-16.1% | 15.1%
Free Cash Flow
12.4%
More
EPS
$-3.9
FCF per Share
$3.0
Short interest
4.1%
Employees
3k
Rev per Employee
$430.0k
Show more

Is Livanova PLC a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,040 stocks worldwide.

Livanova PLC Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Livanova PLC forecast:

12x Buy
75%
4x Hold
25%

Analyst Opinions

16 Analysts have issued a Livanova PLC forecast:

Buy
75%
Hold
25%

Financial data from Livanova PLC

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1,309 1,309
8% 8%
100%
- Direct Costs 405 405
3% 3%
31%
904 904
11% 11%
69%
- Selling and Administrative Expenses 539 539
2% 2%
41%
- Research and Development Expense 177 177
3% 3%
14%
232 232
51% 51%
18%
- Depreciation and Amortization 43 43
7% 7%
3%
EBIT (Operating Income) EBIT 189 189
77% 77%
14%
Net Profit -211 -211
1,174% 1,174%
-16%

In millions USD.

Don't miss a Thing! We will send you all news about Livanova PLC directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Livanova PLC Stock News

Neutral
Business Wire
3 days ago
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Vladimir Makatsaria, Chief Executive Officer, and Alex Shvartsburg, Chief Financial Officer, will present a general business update during a fireside chat at the Wolfe Research Healthcare Conference 2025 in New York City. The presentation will take place Mon., N...
Positive
Seeking Alpha
4 days ago
LivaNova remains a 'BUY' with a raised price target of $61/share, reflecting strong recent results and long-term growth potential. LIVN delivered double-digit revenue growth, improved margins, and raised guidance, driven by Cardiopulmonary and Neuromodulation segment performance. Despite a 20% short-term return, I see further upside due to robust fundamentals, market expansion, and clinical mil...
Neutral
Business Wire
18 days ago
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2025 results on Wed., Nov. 5, 2025, at 1 p.m. London time (8 a.m. Eastern Standard Time). The Company will release its third-quarter 2025 results prior to the call. The audiocast will be accessible at www.livanova.com/events. ...
More Livanova PLC News

Company Profile

LivaNova Plc is a global medical technology company, which engages in the development and delivery of important therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems. It operates through the following segments: Cardiovascular and Neuromodulation. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and advanced circulatory support products. The Neuromodulation segment designs and markets NM-based medical devices for the treatment of epilepsy, depression, and obstructive sleep apnea. The company was founded on February 20, 2015 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Vladimir Makatsaria
Employees 2,900
Founded 1987
Website www.livanova.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today